![Jean-Paul Kress](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Paul Kress
Profile
Jean-Paul Kress currently works at Vor Biopharma, Inc., as Chairman, President & Chief Executive Officer from 2025, Syntimmune, Inc., as President & Director, and Sanofi, as Independent Director from 2025.
Dr. Kress also formerly worked at Sanofi Pasteur MSD SNC, as President & Chief Executive Officer from 2011 to 2015, MorphoSys AG, as CEO & Chairman-Management Board from 2019 to 2024, ERYTech Pharma SA, as Chairman from 2019 to 2023, Sarepta Therapeutics, Inc., as Independent Director from 2015 to 2017, Quantum Genomics SA, as Director from 2018 to 2019, Biogen, Inc., as President-International & Executive Vice President from 2017 to 2018, Genzyme Corp., as Senior Vice President & Head-North America from 2015 to 2017, Gilead Sciences SAS, as Vice President-US Sales & Marketing, and Abbott France SAS, as General Manager-Denmark.
Dr. Kress received his undergraduate degree in 1991 and graduate degree in 1992 from École Normale Supérieure and doctorate degree in 1991 from Faculté De Médecine Necker Enfants Malades Université.
Jean-Paul Kress active positions
| Companies | Position | Start |
|---|---|---|
| SANOFI | Director/Board Member | 31/12/2024 |
| VOR BIOPHARMA INC. | Chief Executive Officer | 24/06/2025 |
Syntimmune, Inc.
 Syntimmune, Inc. Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | President | 02/01/2018 |
Former positions of Jean-Paul Kress
| Companies | Position | End |
|---|---|---|
| MORPHOSYS AG | Chief Executive Officer | 05/06/2024 |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Chairman | 22/06/2023 |
| QUANTUM GENOMICS | Director/Board Member | 23/06/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 31/12/2017 |
| SAREPTA THERAPEUTICS, INC. | Director/Board Member | 05/06/2017 |
Training of Jean-Paul Kress
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Develops and manufactures specialty therapeutic, surgical and diagnostic products | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
École Normale Supérieure
 École Normale Supérieure Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Health Technology |
Quantum Genomics SA
 Quantum Genomics SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cardiovascular diseases | Health Technology |
Gilead Sciences SAS
 Gilead Sciences SAS Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Sanofi Pasteur MSD SNC
 Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Abbott France SAS
 Abbott France SAS Wholesales pharmaceutical products | |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. Engages in developing cell therapies | |
Faculté De Médecine Necker Enfants Malades Université
 Faculté De Médecine Necker Enfants Malades Université Functions as a College/University |
- Stock Market
- Insiders
- Jean-Paul Kress
